Table 3_Targeting DPP9 attenuates podocyte injury by regulating NRF2 antioxidant signaling.docx

Despite the efficacy of finerenone in mitigating CKD progression, its precise cytoprotective mechanisms within podocytes remain incompletely defined. This study aimed to elucidate the role of dipeptidyl peptidase 9 (DPP9) in podocyte injury and determine whether finerenone exerts its renoprotective effects via DPP9‐mediated antioxidant effects.</p>Methods<p>Integrated bioinformatic analyses of single‐cell and bulk transcriptomic databases (KIT, NephroSeq) were performed, with validation in renal biopsies from patients with diabetic kidney disease (DKD) and in murine models of DKD and adriamycin‐induced nephropathy.

In vitro, immortalized human podocyte (HPC) cells were stimulated with high glucose or adriamycin, with DPP9 knockdown or overexpression. RNA sequencing and immunoprecipitation assays were utilized to explore the underlying molecular mechanisms and protein interactions.</p>Results<p>DPP9 was significantly downregulated in injured podocytes from both human and murine models. DPP9 overexpression activated NRF2‐mediated antioxidant responses, protecting podocytes from injury, whereas DPP9 depletion exacerbated cellular damage.